Profile data is unavailable for this security.
About the company
Ocumension Therapeutics is a company primarily engaged in the research, development and commercialization of ophthalmic pharmaceuticals. The products primarily include OT-401 Yutiq fluocinolone intravitreal implant, OT-702 Boyoujing aflibercept intravitreous injection, OT-402 Visudyne, OT- 204 Ou Qin sodium hyaluronate eye drops and OT-305 Betoptic S betaxolol hydrochloride and others. The products are used to treat various anterior and posterior segment eye diseases, such as uveitis, fundus diseases, refractive correction, dry eye disease (DED), glaucoma and conjunctivitis. The Company primarily operates its business in the domestic market.
- Revenue in HKD (TTM)617.89m
- Net income in HKD-283.25m
- Incorporated2018
- Employees505.00
- LocationOcumension TherapeuticsNo. 1858 Yinzhongnan RoadGuoxiang Subdistrict, Wuzhong DistrictSUZHOU KY1-1205ChinaCHN
- Websitehttps://www.ocumension.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM Vaccine Co Ltd | 1.43bn | -305.80m | 3.66bn | 1.49k | -- | 0.9736 | -- | 2.55 | -0.2515 | -0.2515 | 1.18 | 3.06 | 0.174 | 0.7724 | 1.12 | 934,678.40 | -3.71 | -8.04 | -6.66 | -12.31 | 71.80 | 79.64 | -21.32 | -39.38 | 0.5882 | -3.70 | 0.3341 | -- | 8.22 | 6.19 | 78.69 | -- | -7.20 | -- |
| Shandong Boan Biotechnology Co Ltd | 860.02m | 36.40m | 4.41bn | 714.00 | 111.03 | 1.76 | 33.33 | 5.13 | 0.0639 | 0.0639 | 1.51 | 4.02 | 0.2530 | 1.34 | 1.73 | 1,057,833.00 | 1.07 | -- | 1.41 | -- | 71.70 | -- | 4.23 | -- | 1.45 | 1.81 | 0.2827 | -- | 17.50 | -- | 161.31 | -- | -- | -- |
| VIVA Biotech Holdings | 2.09bn | 195.79m | 4.45bn | 2.09k | 29.38 | 0.9967 | 8.82 | 2.13 | 0.0711 | 0.0711 | 0.6839 | 2.10 | 0.2612 | 4.24 | 4.94 | 1,011,754.00 | 3.22 | -1.28 | 3.81 | -1.56 | 37.44 | 34.30 | 12.33 | -4.94 | 1.44 | -- | 0.2283 | -- | -7.84 | 43.80 | 244.08 | -8.85 | 27.82 | -- |
| Beijing Luzhu Biotechnology Co Ltd | 0.00 | -154.40m | 4.89bn | 197.00 | -- | 5.88 | -- | -- | -0.7693 | -0.7693 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -12.48 | -- | -13.69 | -- | -- | -- | -- | -- | 4.68 | -- | 0.2296 | -- | -- | -- | 32.53 | -- | -- | -- |
| Tong Ren Tang Technologies Co Ltd | 7.90bn | 490.60m | 5.42bn | 3.89k | 11.04 | 0.6534 | 4.36 | 0.6862 | 0.383 | 0.383 | 6.16 | 6.47 | 0.482 | 0.8615 | 6.00 | 1,978,414.00 | 5.47 | 7.44 | 8.57 | 12.07 | 39.82 | 42.21 | 11.34 | 15.10 | 2.79 | -- | 0.1913 | 39.34 | 7.18 | 10.15 | -11.59 | 4.55 | -8.30 | 3.37 |
| Ocumension Therapeutics | 617.89m | -283.25m | 5.42bn | 505.00 | -- | 1.30 | -- | 8.78 | -0.3781 | -0.3781 | 0.8251 | 5.10 | 0.1571 | 4.30 | 3.35 | 1,263,572.00 | -7.20 | -24.03 | -7.62 | -25.71 | 42.58 | 58.38 | -45.84 | -400.90 | 4.86 | -- | 0.0223 | -- | 69.38 | 365.95 | 29.36 | -- | 213.01 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.71bn | 515.36m | 7.13bn | 789.00 | 13.84 | 1.77 | 11.36 | 4.17 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| SSY Group Ltd | 4.58bn | 658.92m | 7.13bn | 5.70k | 11.03 | 0.9985 | 6.35 | 1.56 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| China Shineway Pharmaceutical Group Ltd | 3.80bn | 941.22m | 7.56bn | 2.87k | 7.34 | 0.8517 | 9.66 | 1.99 | 1.25 | 1.25 | 5.03 | 10.73 | 0.3299 | 1.15 | 3.81 | 1,180,191.00 | 8.17 | 8.29 | 10.75 | 10.38 | 73.36 | 74.83 | 24.77 | 18.67 | 3.39 | -- | 0.0419 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
Data as of Mar 04 2026. Currency figures normalised to Ocumension Therapeutics's reporting currency: Hong Kong Dollar HKD
11.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 18 Oct 2024 | 40.82m | 4.88% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 26.82m | 3.21% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 13.26m | 1.59% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 4.24m | 0.51% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 2.83m | 0.34% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 2.51m | 0.30% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 2.51m | 0.30% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 2.41m | 0.29% |
| Caitong Fund Management Co., Ltd.as of 30 Jun 2025 | 1.57m | 0.19% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 1.36m | 0.16% |
More ▼
Data from 30 Jun 2025 - 20 Feb 2026Source: FactSet Research Systems Inc.
